



(51) International Patent Classification:

A61K 31/454 (2006.01) A61K 45/06 (2006.01)
 A61K 31/506 (2006.01) A61P 35/00 (2006.01)
 A61K 31/5377 (2006.01) G01N 33/48 (2006.01)
 A61K 31/635 (2006.01) C12Q 1/68 (2006.01)
 A61K 31/675 (2006.01)

(21) International Application Number:

PCT/US2010/058549

(22) International Filing Date:

1 December 2010 (01.12.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12/630,957 4 December 2009 (04.12.2009) US

(71) Applicant (for all designated States except US): **ABBOTT LABORATORIES** [US/US]; 100 Abbott Park Road, Abbott Park, Illinois 60064 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SHAH, Omar Jameel** [US/US]; 25327 W. Columbia Bay Drive, Lake Villa, Illinois 60046 (US). **SHEN, Yu** [CN/US]; 7227

Buchanan Drive, Gurnee, Illinois 60031 (US). **LIN, Xiaoya** [CN/US]; 34198 Old Walnut Circle, Gurnee, Illinois 60031 (US). **ANDERSON, Mark** [US/US]; 410 Sommerset Drive, Grayslake, Illinois 60030 (US). **HUANG, Xiaoli** [US/US]; 12545 Meadow Circle, Lake Bluff, Illinois 60044 (US). **LI, Junling** [US/US]; 1220 Vista Drive, Gurnee, Illinois 60031 (US). **LI, Leiming** [US/US]; 1166 Gail Drive, Buffalo Grove, Illinois 60089 (US).

(74) Agent: **MANZARI, Oona A.**; Abbott Laboratories, 100 Abbott Park Road, AP6A-1/Dept. 0377, Abbott Park, Illinois 60064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: COMBINATION THERAPY FOR TREATING CANCER AND DIAGNOSTIC ASSAYS FOR USE THEREIN




FIG. 1

(57) Abstract: The present disclosure relates to a combination of therapeutic agents for use in treating a patient suffering from cancer, wherein said combination comprises at least one polyploidy inducing agent and at least one Bel - 2 family protein inhibitor. In addition, the present disclosure also relates to diagnostic assays useful in classification of patients for treatment with one or more therapeutic agents.



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*